All articles tagged with #weight loss medications
President Trump announced a deal to expand Medicare coverage for weight-loss drugs like Ozempic and Wegovy, reducing costs for beneficiaries and potentially increasing federal spending by at least $35 billion from 2026 to 2034, amid ongoing concerns about the national debt.
Weight loss drugs like Wegovy and Mounjaro not only suppress hunger but also alter taste perceptions and reduce the reward value of unhealthy foods, leading to changes in food preferences and potentially improving dietary habits, though side effects like gastrointestinal discomfort can also influence eating behavior.
The FDA has begun cracking down on telehealth companies like Hims & Hers for promoting unapproved and misleading versions of prescription drugs, including weight loss medications, as part of a broader effort to ensure truthful pharmaceutical advertising. The agency sent over 100 cease and desist letters to companies making false claims, highlighting concerns over online drug promotion and advertising practices that may mislead consumers about drug safety and efficacy.
TRICARE covers certain weight loss medications like Wegovy and Zepbound for eligible beneficiaries under specific conditions, including enrollment in certain plans and medical criteria, with upcoming regulatory changes taking effect in August 2025. Patients should consult their providers for coverage details and alternative options if needed.
Whoopi Goldberg and Sunny Hostin have spoken out about using weight loss medications, with Goldberg revealing she turned to Mounjaro after hitting almost 300 pounds during the filming of the 2022 film Till, while Hostin dropped 40 pounds after being prescribed the same medication. Their comments came in response to Oprah Winfrey's recent special on weight loss, with Winfrey herself having announced her departure from the WeightWatchers board of directors and donation of her stock in the company to avoid potential conflicts of interest.
New weight loss medications like Wegovy and Zepbound are changing the landscape of medical weight loss, offering hope to individuals like Kim Reitz who struggled with maintaining weight loss. These medications, prescribed at various medical weight loss programs, have gained acceptance and are sought after by patients due to their effectiveness in controlling weight gain. While they offer promise, there are drawbacks such as high costs and the need for long-term use. Medical professionals emphasize the importance of a comprehensive approach to obesity treatment, including medication, diet, exercise, and behavioral support.
The Academy of Nutrition and Dietetics emphasizes the need for nutrition therapy alongside anti-obesity medications, stating that medications alone will not end obesity. The statement comes on World Obesity Day, highlighting the importance of a collaborative, interprofessional approach and policy changes to reduce health inequity and disparity. While the popularity of weight-loss medications like GLP-1 receptor agonists has surged, experts stress the necessity of combining medication with proper nutrition and exercise for effective obesity management.
Oprah Winfrey is stepping away from WeightWatchers and donating her shares to charity due to a perceived conflict of interest around her use of weight-loss medications, particularly GLP-1 drugs like Ozempic. This move reflects a broader cultural shift away from traditional dieting methods and towards reliance on pharmaceuticals for weight loss. The rise of GLP-1 drugs is challenging societal attitudes towards weight and morality, as well as disrupting the diet culture. Additionally, other news includes France's plan to enshrine abortion as a constitutional right, efforts to spotlight women's art in museums, concerns about microplastics in placental tissue, and a surprising observation of male humpback whales engaging in sexual behavior.
Oprah Winfrey is set to depart from the board of WeightWatchers after nearly a decade, amid the company's declining profits and public support. She plans to donate her stake in the company and proceeds from any future stock options to the National Museum of African American History and Culture. The decision comes as WeightWatchers faces criticism for embracing weight loss medications, a departure from its traditional behavior-based program, with CEO Sima Sistani acknowledging that the company's previous advice was wrong and detrimental to people dealing with chronic weight issues.
Experts have raised concerns about the lack of research on the impact of popular weight loss medications, such as semaglutide, on eating disorders. While these medications may potentially help reduce binge eating, there is limited evidence to support their use for treating eating disorders. The suppressive effects on appetite could disconnect individuals from their natural hunger and fullness cues, potentially triggering or reigniting eating disorder behaviors. Experts emphasize the need for thorough screening and caution when prescribing these medications, as well as the importance of addressing eating disorders before considering weight loss treatments.
Research suggests that weight loss medications used for diabetes and obesity, such as the GLP-1 drug liraglutide, may help reduce opioid cravings in people with opioid use disorder. A small study found that those taking liraglutide reported 30% fewer cravings than those who took a placebo, and those taking buprenorphine alongside liraglutide were more likely to report experiencing no cravings at all. While the findings are based on a small sample size and more data is needed, they align with other reports indicating that GLP-1 medications can help treat substance use disorders. Clinical trials are underway to further investigate the potential benefits of these medications for managing opioid addiction.
The demand for new weight loss and diabetes medications, such as semaglutide and tirzepatide, has surged, but the supply has not kept up, leading some people to resort to ordering the drugs online or through compounding pharmacies, which can be risky. Here are five things to consider if you plan to try these medications: consult with a trusted healthcare provider, prepare for potential gastrointestinal side effects, be aware of potential supply shortages, check insurance coverage, and understand that these drugs are not suitable for everyone.
The new weight loss and diabetes medications, such as semaglutide and tirzepatide, have seen a surge in demand due to their effectiveness in helping people lose weight and manage diabetes. However, the supply has not kept up, leading to shortages and potential risks of obtaining fake versions online. It's important to consult a trusted healthcare provider before considering these medications, as they come with potential side effects and may be difficult to obtain due to limited supply and high costs.
The new weight loss and diabetes medications, such as semaglutide and tirzepatide, have seen a surge in demand due to their effectiveness, but supply has not kept up. Patients should consult a healthcare provider before considering these medications, as they can have powerful effects and may cause gastrointestinal issues. Some dosages are in short supply, and insurance coverage can be difficult, with out-of-pocket costs reaching $1,000 a month. Not everyone may be suitable for these drugs, and it's important to make a personal decision in consultation with a doctor.
The demand for new weight loss and diabetes medications, such as semaglutide and tirzepatide, has surged, but the supply has not kept up, leading to shortages and potential risks of ordering online or through compounding pharmacies. It's crucial to consult a healthcare provider before considering these medications, as they can have powerful effects and potential side effects. Additionally, some dosages may be in short supply, they can be expensive, and insurance coverage may be limited. The decision to take these medications should be made in consultation with a doctor, considering both health and personal factors.